Prevent Vaccine Production Delays: Design, Scale‑Up, and Quality Assurance

SARS‑CoV‑2 vaccine production has faced delays, leaving many countries short of the doses they contracted. Even a few weeks’ lag can ripple through public health, politics and society. Vaccine manufacturing is a sophisticated, time‑consuming bioprocess that must pass multiple filtration, purification and quality checkpoints. Yet the root causes of delays remain opaque. Common issues include reduced yields,¹ compromised quality or cleanliness,² and scale‑up challenges,³ echoing the FDA’s finding that 62% of drug shortages stem from manufacturing or product quality problems.⁴

How can manufacturers proactively prevent such setbacks?

Design for Manufacturing

Complex, sensitive processes demand a deep understanding of every variable and its limits. By applying Design of Experiments (DoE) techniques, manufacturers can uncover cause‑and‑effect relationships, pinpoint critical process parameters (CPPs), and expand operating ranges that boost yield while safeguarding quality.

Scale‑Up

Translating a small‑scale process to commercial production requires meticulous unit‑operation planning. CPPs and critical quality attributes (CQAs) are identified during development and must be faithfully reproduced at scale. When predictions fall short, additional full‑scale runs are needed to refine conditions and uncover hidden parameters. A validated, quality‑by‑design (QbD) framework accelerates time‑to‑market and reduces surprises.

Avoid Failure

Late detection of process drift can render entire batches unusable, forcing costly re‑runs and investigations. Large‑molecule biologics amplify this risk due to their complexity and sensitivity. Robust monitoring and early warning systems—alongside rapid root‑cause analysis—are essential to prevent recurrence and protect supply.

Control Your Process

Regulatory compliance and product consistency hinge on continuous process verification (CPV). This requires seamless data integration from lab to production floor, real‑time identification of CPPs and CQAs, and automated alerts that trigger review‑by‑exception workflows. Such vigilance guarantees the process remains within design intent, delivering the promised yield and quality.

Enable Your CDMOs

Vaccine production often spans multiple sites and Contract Development & Manufacturing Organizations (CDMOs). Successful transfer demands a baseline of process performance and clear operational requirements. Defining valid operating ranges enables new sites or CDMOs to replicate a stable, validated process quickly, ensuring timely delivery.

Manufacturing Analytics

BioVIA’s Discoverant offers a validation‑ready analytics platform that aggregates and contextualizes process and quality data. It identifies CPPs, operating ranges and CQAs, supporting scale‑up and transfer for both in‑house and contract operations. With automated alerts and signal‑monitoring dashboards, Discoverant turns months of root‑cause investigation into hours, fostering rapid decision‑making across internal and external networks.

Optimize processes, product quality, yield, and collaboration in vaccine production.

Avoid product shortages and meet contractual delivery obligations with Discoverant!